Yersinia is a gram positive rod-shaped bacteria belonging to the family Enterobacteriaceae. It generally causes enterocolitis, terminal iletis, acute diarrhea, mesenteric lymphadenitis, psediappendicitis, and sepsis. Pathogenic species of Yersinia include Yersinia pestis, Yersinia enterocolitica, and Yersinia pseudotuberculosis. Yersinia is a food borne bacteria that enters the human body through unhygienic, canned, and stale food. Pigs are the main animal reservoir of Yersinia, but strains are also found in rodents, dogs, cattle, rabbits, sheep, cats, and horses. The bacteria enter into human beings through these animals. Clinical signs for diagnosis of Yersinia infection include low grade fever, abdominal pain, diarrhea, and vomiting. Patients sometimes also develop erythmanodosum, which results in painful red or purple lesions on the legs. These lesions are visible after 2 to 20 days post the onset of fever and abdominal pain. Yersinia infections affect men three times more than women, but post-infection complications of arthritis and nodosum are more common in women. Yersinia usually occurs in children and is the second most common cause of bacterial gastrointestinal infection. For confirming Yersinia infection in patients, doctors sometimes perform laboratory diagnosis after serological tests to support the associated syndromes. Treatment of Yersinia infections includes drugs such as aminoglycosides, cephalosporins, tetracyclines, trimethoprim-sulfamethoxazole (TMP-SMZ), and fluoroquinolones.
Factors such as technological advancements, awareness about health in developing countries, greater adoption of novel molecular diagnostic tools, and increase in the number of patients are likely to boost the Yersinia diagnostic market in the near future. However, factors such as stiff competition among existing Yersinia diagnostics manufacturers, government regulations for the reduction of overall health care costs, and rise in bulk purchasing through group purchasing organizations (GPOs) are anticipated to hamper the Yersinia diagnostic market in the coming years. Moreover, the development of more sensitive, efficient, and yet simple rapid diagnostic systems that can be applied to direct and indirect diagnosis still remains a challenge in this Yersinia diagnostic market.
The global Yersinia diagnostic market can be segmented based on test, technology, end-user, and geography. Based on test, the Yersinia diagnostic market can be classified into stool culture, ELISA, radioimmunoassay, tube agglutination, CT scan, ultrasonography, colonoscopy, and others. In terms of technology, the Yersinia diagnostic market can be categorized into DNA probes, immunoassay, monoclonal antibodies, PCR, and others. Based on end-user, the Yersinia diagnostic market can be divided into hospital laboratories, public health laboratories, commercial laboratories, and others. The hospital laboratories segment is likely to hold a major share of the Yersinia diagnostic market as diagnostic tests for in-patients and premium chargers applied for test in hospitals.
In terms of geography, the Yersinia diagnostic market can be classified into North America (the U.S. and Canada), Europe (Germany, France, the U.K., Italy, Spain, etc.), Asia Pacific (Australia, China, Japan, India, etc.), Latin America (Brazil, Mexico, Argentina, etc.), and Middle East & Africa (GCC countries, South Africa, etc.). In 2017, North America was a significant region of the Yersinia diagnostic market in terms of revenue. The Yersinia diagnostic market in Europe is expected to expand at a rapid pace in the near future. The Yersinia diagnostic market in emerging regions such as Asia Pacific, Latin America, and Middle East & Africa is anticipated to expand at a robust pace between 2018 and 2026. This is due to expansion in the health care industry and an aging population, which consequently would lead to increased patient population in these countries. India, China, and Brazil are expected to be rapidly expanding countries of the Yersinia diagnostic market, owing to increase in investments by government bodies in order to enhance health care facilities.
Major players operating in the Yersinia diagnostic market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic Inc., Danaher Corporation, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Thermo Fisher Scientific Inc.,
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.